关于我们
GREINER BIO-ONE 带来变化
Our performance in 2024
Compared to 2023, our customers' stock levels have increasingly eased in 2024, resulting in a more balanced demand situation.
The Preanalytics business unit recorded satisfactory demand overall, and in the BioScience segment, demand stabilized after a significant decline in the previous year and the first half of the current year.
Outlook for 2025: Profitable growth
This year, Greiner Bio-One remains focused on profitable growth and looks ahead with confidence to the economic developments of 2025.
The stabilization of the market situation in recent months provides a solid foundation for this. In the Preanalytics and BioScience business units, Greiner Bio-One is building on its core products to further strengthen its market position. Beyond its home markets in Europe, the company sees significant potential in the United States, aiming to further expand its global market share, particularly in BioScience.
Greiner Bio-One is also optimistic about the future of its Sterilization business unit, with its subsidiary Mediscan and the site expansion in Kremsmünster, Austria. With this investment in state-of-the-art plant technology, Mediscan is well-positioned to meet the growing demand from third-party customers in the sterilization sector.
“我们希望为医学领域的卓越成就做出贡献，并为用户和患者带来真正的改变。”
销售额
| 年 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| 销售额 | 4.73 | 5.09 | 6.93 | 6.95 | 6.93 | 6.37 | 6.66 |
格瑞纳可持续发展年度报告
Greiner Bio-One 企业视频
对我们来说，健康是每个人的最重要的事。这激励着我们的日常使命，即以先进、可持续的产品和解决方案服务于生命科学和医护专业人士。正是我们员工的热情和奉献精神使我们与众不同。我们的全球团队与我们的客户紧密合作，不断追求卓越。这就是我们为预分析、科学研究和生物技术提供产品解决方案的原因所在。无论您在世界何处需要我们，我们都竭诚为您提供服务。
Core Business
Greiner Bio-One has been developing and distributing solutions and high-quality plastic products for medical technology and laboratory applications for more than 60 years. Its products are used in clinical diagnostics (e.g. blood and saliva collection systems), life science research (e.g. cell culture products), drug discovery (e.g. microplates), and the sterilization of medical devices. With a broad portfolio available in over 100 countries worldwide, the company supports scientists and medical professionals in their daily work caring for patients. Greiner Bio-One operates in the market through its three business units:
Preanalytics → develops and manufactures systems for taking blood and urine samples from people and animals. It also provides digital systems for pre-analytics. Indwelling venous safety cannulas round out the portfolio. The innovative product solutions from Preanalytics significantly improve the efficiency and safety of daily routine tasks in a hospital, laboratory, or clinical setting. This division also covers customised software solutions Tracie Healthcare Solutions which ensure greater efficiency and patient safety in the preanalytical process.
Mediscan → is one of Europe’s leading suppliers and service providers in the sterilization of medical products, the sterilization of food packaging, and the functional improvement of plastics and semiconductors using ionizing radiation.
BioScience → is a strong technology partner for universities, research institutions, and players in the diagnostic,
pharmaceutical, and biotech fields. The business unit focuses on developing and producing laboratory quipment, such as containers for cultivating and analyzing cell cultures, as well as microplates used for high-throughput screening in biochemical, genetic, and pharmacological tests.
As an Original Equipment Manufacturer (OEM), Greiner Bio-One is also a solid partner for industry clients working in pharmaceuticals, biotechnology, diagnostics and medical technology and offers customised design development and production processes.
“Our central objective is to ensure that: We embody our values and our conduct is legally and ethically impeccable! The Management Board will do everything in its power to ensure that the standards established in this code of conduct are permanently implemented and respected in all parts of the Group. ”
拥有近150年历史的Greiner集团，在过去的几年里，已经成为了真正的全球化企业。我们在全球拥有超过125个分支机构，与客户关系密切，可以灵活地响应他们的需求。但是，这样一个复杂的组织也带来了挑战。
我们希望此行为准则能够作为公司长期保持积极发展的基础。这套行为准则植根于Greiner的理念中，它强调集团的全球定位、作为雇主和服务提供商的吸引力以及卓越的行为准则。我们将这些原则所衍生的行为准则写入行为准则，并提供给所有员工、客户和业务伙伴。从长远来看，这应该有助于我们保证我们的行为规范的完整性。
我们的核心目标是确保：我们体现了我们的价值观，我们的行为在法律和道德上都是无懈可击的!
管理委员会将尽其所能，确保本行为准则中规定的标准在集团的所有部门得到长期执行和遵守。树立良好的榜样是我们深思熟虑的愿望，也是我们的既定目标。我们邀请所有员工在这条道路上与我们一起努力。
在任何经济体系中，研发一直是增长的驱动力之一。特别是医疗技术和生物技术在过去的几十年中稳步增长。
Greiner Bio-One的商业成功基于现代技术的不断进步，公司营业额的很大一部分用于研发。在奥地利和德国的工厂中，来自各个领域的产品专家团队正在努力设计和实施创新的解决方案。
在Greiner Bio-One，微生物学、化学、物理和塑料工程领域的专家致力于开发新工艺和新产品。Greiner Bio-One在Kremsmünster（上奥地利州）拥有最先进的研究中心，用于开发基于DNA阵列的分子生物学分析方法。我们会开展临床研究，并在公司内部的临床实验室中进行性能评估测试。
我们和众多公司，公共机构和组织成为了合作伙伴，这意味着Greiner Bio-One始终能够尽早发现相关问题、最新发展和新兴趋势，并将其转化为产品解决方案。
作为医学研究高质量产品的供应商和诊断试剂的制造商，我们对使用我们的产品在全球研究机构、实验室和医院进行的无数分析承担责任。我们将客户50年的信心视为我们提供了最高质量标准的证明，也有义务继续进一步提高产品质量。
Greiner Bio-One追求质量第一。所有生产基地均已通过ISO 9001和ISO 13485认证，并且满足众多的国家和国际质量要求。通过使用最先进的生产技术，在特殊的环境条件下进行制造并部署高技能的员工，我们不断提高产品和工艺的质量。
Greiner Bio-One采用精心开发的质量保证体系，以完全满足所有客户的要求。我们的优化流程涵盖了整个供应链，从精心选择供应商到开发和产品的生产，再到产品的销售。所有产品均按照适用的法律规定贴有标签，并且可以追溯到所使用的组件和供应商。
产品和生产过程由国家和国际主管部门及授权机构定期审计。我们的员工对生产的每个阶段进行持续、系统的监控，确定可以在何处进行改进并最大程度地发挥这一潜力，以确保卓越的产品质量。我们努力优化所有流程，以使客户受益。风险管理是我们质量方针的核心要素。
最好的质量管理体系取决于应用它的人。我们特别关注整个Greiner Bio-One团队的培训、资格认证和持续发展。我们定期为员工举办质量和产品培训课程，向他们展示如何使用所有Greiner Bio-One产品，以及相应的质量要求。通过这些措施，我们可以在日常工作中为客户实现最高的质量标准。
关于我们业务部门的细节
我们专注于以客户为导向，提高产品质量，并从各个领域提供创新的产品解决方案。
We would like to direct you to the correct site for your country.